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Abstract 31 
Introduced for mass immunization in the 1920s, vaccines against diphtheria are among the oldest 32 
and safest vaccines known. The basic principle of their production is the inactivation of purified 33 
diphtheria toxin by formaldehyde cross-linking, which converts the potentially fatal toxin in a 34 
completely harmless protein aggregate, which is still immunogenic. Since in addition to diphtheria 35 
toxin also other proteins may be secreted by Corynebacterium diphtheriae during cultivation, we 36 
assumed that diphtheria toxoid might not be the only component present in the vaccine. To address 37 
this question, we established a protocol to reverse formaldehyde cross-linking and carried out mass 38 
spectrometric analyses. Different secreted, membrane-associated and cytoplasmic proteins of C. 39 
diphtheriae were detected in several vaccine preparations from across the world. Based on these 40 
results, bioinformatics and Western blot analyses were applied to characterize if these proteins are 41 
immunogenic and may therefore support protection against C. diphtheriae. In frame of this study, we 42 
could show that the C. diphtheriae toxoid vaccines induce antibodies against different C. diphtheriae 43 
proteins and against diphtheria toxin secreted by Corynebacterium ulcerans, an emerging pathogen 44 
which is outnumbering C. diphtheriae as cause of diphtheria-like illness in Western Europe. 45 
 46 
1. Introduction 47 
Diphtheria is an infection of the upper respiratory tract of humans and was a major cause of 48 
morbidity and mortality especially of children until the beginning of the 20th century (for recent 49 
reviews, see [1-3]). In 1884 Löffler showed that Corynebacterium diphtheriae is the etiological agent 50 
of diphtheria and postulated that a toxin secreted by this bacterium is responsible for the often fatal 51 
damages observed to heart and kidneys [4]. This hypothesis was verified by Roux and Yersin 52 
(1888). When filter-sterilized supernatants of C. diphtheriae cultures were injected to guinea pigs, 53 
damages similar to those observed in cases of human diphtheria infections were found [5]. Classical 54 
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diphtheria of the upper respiratory tract is spread from person to person by respiratory droplets 55 
produced by coughing. Additionally, other secretions and contaminated materials may be sources of 56 
infection especially in cases of cutaneous diphtheria. After infection and colonization of 57 
nasopharyngeal epithelia by the bacteria within two to five days, patients are infectious for two to 58 
three weeks. Today, penicillin and erythromycin are drugs of choice to stop the infection [6] and 59 
quickly render patients non-infectious [7]. Before introduction of mass vaccination, diphtheria was 60 
observed as an infection especially of children, indicating that C. diphtheriae was widely 61 
disseminated among the population leading to early contact with the pathogen.  62 
The development of vaccines starting in the 1920s and the introduction of mass 63 
immunization using diphtheria toxoid vaccines led to a dramatic reduction of worldwide diphtheria 64 
cases. After the global introduction of the “Expanded Programme on Immunization” (EPI) in 1974, 65 
only relatively small and local outbreaks occurred until the 1990s [8]. However, with the breakdown 66 
of the former Union of Socialist Soviet Republics, a large scale outbreak was observed, leading to a 67 
diphtheria pandemic with more than 157,000 cases and over 5,000 deaths reported between 1990 68 
and 1998 [9-12]. The outbreak started in the Russian Federation [13-15], but it quickly spread to the 69 
Baltic States, former Asian Soviet Republics and other states such as Finland, Poland and Turkey 70 
[16]. In contrast to former epidemics, children were less affected, while diphtheria cases among 71 
adolescents and adults reached up to four fifths of total cases in some states [9,17]. The outbreak 72 
was finally stopped by mass immunization, especially of adults. Despite this success and the 73 
continuing global EPI, diphtheria is not eradicated today and its etiological agent C. diphtheriae is 74 
still present on the list of the most important global pathogens [18,19]. In fact, reported global cases 75 
increased from about seven thousand in 2016 to almost nine thousand in 2017 with a focus on 76 
countries with poor access to public health systems, for example India, Indonesia, Nepal, Pakistan, 77 
Venezuela and Yemen [20]. Furthermore, recent analyses of respiratory and cutaneous diphtheria 78 
cases among Spanish, Belgian, German and British citizens as well as in Asian and African 79 
refugees in Finland, Denmark, Germany and Sweden indicated the circulation of toxigenic C. 80 
diphtheriae not only among immigrants, but also among the indigenous population of the European 81 
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Union [21-25]. Among toxigenic C. diphtheriae isolates, the highly virulent ‘Sankt-82 
Petersburg/Rossija’ epidemic clone that caused the large diphtheria outbreak in Russia and 83 
neighboring countries in the 1990s is still in circulation in the European Union [26]. Moreover, in 84 
Europe the number of cases of human diphtheria-like disease associated with pet animals, i.e. cats 85 
and dogs, has increased, which are caused by Corynebacterium ulcerans, a close relative of C. 86 
diphtheriae [24,27].  87 
Infections with diphtheria can be successfully treated with antitoxin and antibiotics [6]; 88 
however, an efficient vaccination regime is most effective to prevent this potentially fatal disease. 89 
The basis for vaccination was laid by scientists such as Ehrlich, Fraenkel, Park, Ramon, von 90 
Behring and others at the beginning of the 20th century, leading to the development of today’s 91 
diphtheria toxoid vaccine (for review, see [28]). The vaccines are commonly injected intramuscularly 92 
as a 0.5 ml dose and typically combinations with tetanus and pertussis vaccines are administered 93 
(DT and DPT vaccines). The immunization schedule recommended by the World Health 94 
Organization (WHO) includes a primary immunization series of three doses for infants followed by 95 
optional booster immunizations for adults [19]. After the primary immunization series 94 to 100 % of 96 
children develop at least minimal protective antibody levels (> 0.01 IU/ml) [19]. For 2018 the WHO 97 
reported a global estimated diphtheria, tetanus and pertussis (DTP3) coverage of 86 % [29], while 98 
almost 20 million infants worldwide did not receive a routine primary immunization series of DTP3 99 
vaccine [30].  100 
Although diphtheria vaccine is thought to be directed exclusively against the toxin and 101 
immunization is not expected to be prevent carriage of C. diphtheriae on epithelia and skin [31], an 102 
influence of vaccination on the increasing emergence of non-toxigenic strains was discussed [32]. In 103 
this case, diphtheria toxoid vaccines may also prevent bacterial infections due to the presence of 104 
trace amounts of other immunogenic proteins in the vaccine.  105 
This hypothesis seems plausible, when the production process is analyzed in detail. After 106 
cultivation of the most common used toxigenic vaccine strain of C. diphtheriae PW8 [33] in beef-107 
derived peptides or casein hydrolysate, the bacteria are removed by centrifugation [28,34,35]. For 108 
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inactivation of the secreted diphtheria toxin, 0.75 % of formaldehyde is added to the supernatant and 109 
the solution incubated for up to six weeks at 37 °C [35-37]. After the supernatant is fully detoxified, 110 
the toxoid-containing solution is filtered and as further purification and concentration step ammonium 111 
sulfate precipitation is often applied, before the toxoid is tested for potency [28,34,35,38]. To 112 
enhance the immune response, aluminum salts are added as adjuvant to the toxoid vaccine [28]. 113 
This well-established production process makes it very likely, that besides the toxin other secreted 114 
proteins, which were described earlier to be part of culture supernatants of C. diphtheriae [39], are 115 
also present in toxoid preparations. To investigate this hypothesis, we developed a protocol to purify 116 
proteins from commercially available vaccines and reverse the formaldehyde cross-linking, which 117 
was described to be irreversible previously [40]. A number of proteins was identified by mass 118 
spectrometry. Bioinformatics analyses and Western blotting experiments were carried out to 119 
elucidate, if these proteins may contribute to immune protection against C. diphtheriae. 120 
 121 
2. Methods 122 
2.1. Human ethics   123 
Human blood was collected from three adult patients six months after hematopoietic stem cell 124 
transplantation before re-vaccinations (first serum) and one year after three vaccinations with 125 
Pentavac® (DTaP-Hib containing 30 IU of diphtheria toxoid and 40 IU of tetanus toxoid, 126 
SanofiPasteur) (second serum). First booster and second booster vaccinations were given 4 weeks 127 
after the primary or first booster vaccinations, respectively. All methods were performed in 128 
accordance with the relevant guidelines and were approved by the University Hospital Ethics 129 
Committee „Ethik-Kommission der Friedrich-Alexander-Universität Erlangen-Nürnberg“ 130 
(Krankenhausstraße 12, 91054 Erlangen, Germany; https://www.ethikkommission.fau.de) under 131 
registration number 147_12B. All patients enrolled gave written informed consent before 132 
participation. 133 
 134 
2.2. Preparation of vaccines for mass spectrometry analysis 135 
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Since the protein content of the commercial vaccines analyzed in this study (Table 1) was 136 
considered low, multiple vaccine doses (0.5 ml each) were pooled and precipitated by addition of 10 137 
% (w/v) trichloroacetic acid (TCA) and incubation at 4 °C for 16 h to get a concentrated sample for 138 
mass spectrometry analysis [41]. After incubating for 16 h at 4 °C the samples were centrifuged 139 
(8000 x g, 30 min, 4 °C). The precipitated proteins were dried on ice and solved in rehydration buffer 140 
(2 % sodium deoxycholate, 10 mM dithiothreitol (DTT), 50 mM Tris, pH 8.0). To reverse the 141 
formaldehyde cross-linking of the inactivated toxins, the samples were incubated for 20 min at 95 °C 142 
[42]. Subsequently, the protein amount of rehydrated and heat-treated samples was determined 143 
using a spectrophotometer (NanoDrop LITE, Thermo Fisher Scientific, Bremen, Germany) at 280 144 
nm.  145 
 146 
2.3. Tryptic digest and C18 clean up 147 
About 10 µg soluble proteins prepared from the vaccine samples (see above) were transferred to 10 148 
kDa vivacon 500 membrane filters and the flow-through was discarded after centrifugation for 30 149 
min at 12,000 x g to remove all salts from the vaccine (e.g. aluminum adjuvant), TCA precipitation 150 
and rehydration step. The tryptic digest of the prepared vaccines samples occur within modified 151 
Filter Aided Sample Preparation (FASP) protocol [43]. The proteins were reduced by addition of 200 152 
µl of reduction buffer (25 mM DTT, 8 M urea, 50 mM triethylammonium bicarbonate buffer (TEAB)) 153 
for 30 min at 37 °C. Alkylation of sulfhydryl groups was carried out with 200 µl alkylation buffer (25 154 
mM chloroacetamide (CAA), 8 M urea, 50 mM TEAB) for additional 30 min on a shaker at 600 rpm 155 
in the dark. The proteins were subsequently washed with 300 µl of 8 M urea in 50 mM TEAB 156 
followed by another washing step with 200 µl 6 M urea in 50 mM TEAB. Afterwards 0.5 µg mass 157 
spectrometry grade LysC endopeptidase was added onto the filter unit and incubated on a shaker at 158 
37 °C and 600 rpm for 3 h, followed by a second digest with 1 µg trypsin and 250 µl dilution buffer 159 
(50 mM TEAB) to reach a final concentration of 1 M urea. The sample was incubated over-night at 160 
37 °C at 600 rpm on a shaker. Peptides were then collected by centrifugation at 12,000 x g for 20 161 
min. For acidification of the peptide solution 20 µl of 10 % trifluoroacetic acid (TFA) was added to 162 
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reach a final concentration of 0.5 % TFA. To remove all remaining salts a clean-up of the peptides 163 
with C18 stage tips were performed. Prior to LC-MS/MS analysis, peptides were vacuum dried and 164 
solved in 0.1 % trifluoroacetic acid (TFA) [44]. 165 
 166 
2.4. Mass spectrometry 167 
Mass spectrometric analyses were carried out as described [44,45] and resulting raw data files were 168 
analysed using the C. diphtheriae ATCC 700971/NCTC 13129/Biotype gravis database (Proteome 169 
Id: UP000002198) and the Proteome Discoverer 1.4 program package (Thermo Fisher Scientific, 170 
Bremen, Germany). As described by Schäfer and co-workers [46] theoretical masses for peptides 171 
were generated by trypsin digestion with a maximum of 2 missed cleavages. Product ions were 172 
compared to the measured spectra using the following parameters: carbamidomethyl modification 173 
on cysteine was set as fixed and oxidation of methionine as dynamic modification. Mass tolerance 174 
was set to 10 ppm for survey scans and 0.6 Da for fragment mass measurements. For protein 175 
identification the thresholds were set on 1 % false discovery rate (FDR). For each vaccine, between 176 
two and six mass spectrometry runs were carried out (24 in total).  177 
 178 
2.5. Label-free quantitative protein analysis 179 
For protein quantification of vaccines, three single vaccine doses from the Russian vaccine were 180 
prepared and analyzed by mass spectrometry using approximately 250 ng of each sample. The 181 
peak area which correlates with the concentration of peptides was used to determine the quantity of 182 
proteins present in the vaccines [47-49]. Only peaks ranged from 2 x 107 up to 1011 where used for 183 
quantification as described previously [50].  184 
 185 
2.6. Proteome prediction and prevalence of the proteins among other C. diphtheriae strains 186 
Cellular localization and the characteristics of C. diphtheriae proteins identified in different samples 187 
of vaccines were extracted from the previously available data [51]. The prevalence of these proteins 188 
among diverse C. diphtheriae strains was inferred by searching the pan-genome of 117 strains [52]. 189 
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 190 
2.7. Prediction of putative immunogenic proteins 191 
To analyze the role of proteins present in vaccines as putative antigens the VaxiJen database 192 
(http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) was used with a threshold of 0.4 [53].  193 
 194 
2.8. Data availability statement 195 
The mass spectrometry proteomics data of 24 runs carried out have been deposited to the 196 
ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner 197 
repository [54]. Data are available via ProteomeXchange with identifier PXD009289 (Reviewer 198 
account details: username reviewer37203@ebi.ac.uk; password 5Q1HhAzo). 199 
 200 
2.9. Growth conditions 201 
C. diphtheriae and C. ulcerans strains used in this study (Table 2) were grown in Heart Infusion (HI, 202 
Oxoid, Wesel, Germany) at 37 °C under shaking at 125 rpm in baffled flasks. Growth was monitored 203 
by measuring the optical density at 600 nm (OD600). For preparation of protein extracts, bacteria 204 
were inoculated to an OD600 of 0.1 and grown to an OD600 between 0.4 and 0.6, which was reached 205 
after about 4 h. For toxin production 2-2´-bipyridyl was added at a final concentration of 0.5 mM 206 
during exponential phase and bacteria were incubated for further 2 h under iron starvation 207 
conditions [55].  208 
 209 
2.10. SDS-PAGE and Western blotting 210 
For SDS-PAGE of proteins in the Td-pur vaccine, proteins were precipitated, rehydrated (see 211 
section 2.2 for buffers) and incubated at 95 °C for different time intervals. 125 µg of proteins were 212 
loaded per well and separated according to their apparent molecular mass using Tricine-buffered 213 
12.5 % (w/v) polyacrylamide gels [56]. After gel electrophoresis proteins were visualized by silver-214 
staining [57]. 215 
 9 
For SDS-PAGE of cell extracts of the different C. diphtheriae and C. ulcerans strains studied, 216 
bacteria were harvested by centrifugation, resuspended in PBS (0.137 M NaCl, 2.7 mM KCl, 10 mM 217 
Na2HPO4, 2mM KH2PO2, pH 7.4) to identical OD600 equivalents (OD600 of 0.8) and incubated at 95 °C 218 
for 20 min. Protein concentrations of these crude cell extracts were determined using a standard 219 
Bradford assay [58]. Equal amounts (approximately 2 µg protein per slot) of protein extracts from the 220 
bacteria were loaded onto Tricine-buffered 12.5 % (w/v) polyacrylamide gels [56]. After separation 221 
by SDS-PAGE, proteins were transferred onto PVDF membranes using a Bio-Rad semi-dry 222 
apparatus for 1 h at 0.8 mA/cm2. The membranes were washed for 15 min in TBS-T (19.8 mM Tris, 223 
150 mM NaCl, pH 7.6, 0.1 % Tween 20) and subsequently blocked in blocking solution (5 % non-fat 224 
dry milk in TBS-T) for 1 h at 4 °C. Human serum from three different donors (K002, K003 and K009) 225 
and diphtheria antitoxin (DAT) (Microgen, Russia) was used as primary antibody (1:1,000 dilution) 226 
and incubated overnight at 4 °C in blocking solution. After three washing steps in TBS-T, the 227 
secondary antibody (anti human IgG (Fc-specific) alkaline phosphatase antibody, Sigma-Aldrich, 228 
Germany or anti-horse IgG (Fc-specific) alkaline phosphatase antibody, Sigma-Aldrich, Germany) 229 
was incubated in a 1:15,000 dilution in blocking solution for 1 h at 4 °C followed by three washing 230 
steps. Detection of immune-reactive bands was performed with 5-bromo-4-chloro-3-indolyl-231 
phosphate/nitro blue tetrazolium (BCIP/NBT) color development substrate according to the 232 
manufacturer’s protocol. 233 
 234 
3. Results 235 
3.1. Reversibility of formaldehyde cross-linking 236 
Diphtheria toxoid vaccines are among the safest vaccines known. During production, the potentially 237 
fatal diphtheria toxin is inactivated by extensive cross-linking with formaldehyde, carried out at 37 °C 238 
for several days. While short-term formaldehyde cross-linking is reversible, the long treatment in the 239 
vaccine production processes was described to be irreversible. Consequently, it was reported that 240 
mass spectrometric analyses of such vaccines are highly problematic or even impossible [40,59]. In 241 
this study, we developed a protocol to resolve cross-linking of toxoid preparations from different 242 
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sources. When subjected to SDS-PAGE, untreated samples precipitated almost completely in the 243 
wells of the gel and did not enter the polyacrylamide matrix due to extensive cross-linking. Heat 244 
treatment of these samples for increasing time intervals resulted in the appearance of protein bands 245 
with apparent molecular masses between 10 and 70 kDa besides more faint bands in the higher 246 
molecular mass range. The most prominent bands with an apparent molecular mass of 247 
approximately 65, 55 and 45 kDa may represent subunits of diphtheria and tetanus toxin (i.e. the 62 248 
kDa diphtheria toxin with a 22 kDa A and 40 kDa B subunit and the 150 kDa tetanus toxin with a 50 249 
kDa A and 100 kDa B subunit), while the identity of the other bands was unclear (Fig. 1). Therefore, 250 
we started mass spectrometry analyses to identify the proteins present in vaccine preparations with 251 
emphasis on C. diphtheriae. 252 
 253 
3.2. Mass spectrometric analysis of toxoid vaccines 254 
For mass spectrometry analyses, heat-treated vaccine preparations were precipitated by TCA, 255 
purified and subsequently subjected to mass spectrometry. Samples were analyzed in respect to the 256 
total number of proteins present in the all vaccines and producer-specific variations. In the six 257 
vaccines analyzed, 665 different proteins from C. diphtheriae were identified. While the vaccine from 258 
Brazil contained 130 distinct proteins, in the vaccine from Germany 205 different proteins were 259 
found, 324 proteins were detected in the Bulgarian vaccine as well as 344 and 363 proteins, 260 
respectively, in the two different Russian vaccines analyzed. With 436 different proteins the highest 261 
number was detected in the vaccine from India (Fig. 2).  262 
Predictions of protein localization showed a cytoplasmic localization for 456 (69 %) proteins, 263 
93 (14 %) proteins were predicted to be secreted, 90 (13 %) membrane-localized and 26 (4 %) 264 
proteins showed an ambiguous localization. Forty-one percent of the secreted proteins are 265 
lipoproteins including 4 % with a twin-arginine domain, 28 % non-classical secreted proteins, 28 % 266 
proteins with Spl signal peptide, 1 % Tat-secreted proteins without signal peptide, 1 % Tat-267 
dependent proteins with transmembrane domain and 1 % Esx substrate proteins. Twelve percent of 268 
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the membrane-associated proteins were also detected with a signal peptide, 7 % with a LPXTG 269 
domain and 1 % were YidC-like proteins.  270 
Further bioinformatics analyses revealed that out of the 665 distinct proteins detected in the 271 
different vaccines, 456 proteins were described before as a set of proteins conserved among 117 C. 272 
diphtheriae isolates, which was defined as core proteome of these strains [60]. These included 336 273 
cytoplasmic proteins, 57 secreted proteins, 54 membrane proteins and 9 proteins with ambiguous 274 
localization. 65 proteins were present in all six vaccines (Fig. 2a, Table 3). Among these an 275 
enrichment of secreted and membrane proteins was observed compared to the overall identified 276 
proteins (43 % versus 27.5 %) (Fig. 2 b). From the set of 65 proteins detected in all six vaccines 24 277 
proteins were identified in a previously carried out secretome study [39]. Recently, in an in silico 278 
analysis by Hassan and co-workers [61] ten of the 65 proteins were found as conserved target 279 
proteins and four (DIP1902, DIP1303, DIP0470, DIP0281) of them as global drug targets of the 280 
conserved proteome form C. diphtheriae (Table 3) [61]. In addition, the DIP1680 protein was found 281 
in an in silico approach for the identification of therapeutic targets and putative virulence factor by 282 
Jamal and co-workers [62]. 283 
Besides their presence, also the relative amounts of C. diphtheriae proteins were analyzed 284 
for the Russian vaccine. As estimated by label-free protein determination, the peak-area of 285 
diphtheria toxin (DIP0222) represents up to 78.7 ± 7.6 % of the total proteins from C. diphtheriae. 286 
The next prominent single proteins were glutamate dehydrogenase (DIP1547) with 1.1 % ± 0.5 % 287 
and catalase (DIP0281) with 0.8 % ± 0.1 %, while all other proteins accumulated to 19.4 % ± 7.2 %, 288 
(Fig. 3).  289 
 290 
3.3. Prediction of putative immunogenic proteins 291 
Due to the fact, that formaldehyde cross-linking for toxin detoxification is not selective for diphtheria 292 
toxin, each of the proteins present in the culture supernatant is able to react with each other to build 293 
protein complexes. These proteins identified besides the diphtheria toxin in all vaccine samples (see 294 
above) may function as additional antigens during vaccination. Of special interest in this respect 295 
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were proteins of C. diphtheriae, which may have direct contact with the host immune system. 296 
Therefore, all secreted or cell surface-exposed proteins, which were identified in this study in all 297 
vaccines and were found to be conserved among more than hundred C. diphtheriae strains recently 298 
[60], were analyzed in respect to their putative immunogenicity. In fact, 15 out of 16 proteins were 299 
indicated as possible antigens when the VaxiJen database was used to predict immunogenicity of 300 
these proteins.  301 
 302 
3.4. Immuno-reaction of diphtheria antitoxin 303 
Although the diphtheria toxin is obviously the main component of diphtheria toxoid preparations, also 304 
the additionally observed proteins may be immunogenic as predicted by the bioinformatics analyses 305 
presented above. As a first approach to address this idea, commercially available diphtheria 306 
antitoxin (DAT) was tested in Western blotting experiments. The diphtheria antitoxin used was 307 
produced by immunization of horses with toxoid preparations for application in diphtheria cases to 308 
scavenge the diphtheria toxin from the patients’ blood stream.  309 
 The immune reaction of DAT against a selection of three toxigenic and seven non-toxigenic 310 
C. diphtheriae isolates with different strain background and from different countries was tested 311 
(Table 2). Cells were grown in absence and presence of bipyridyl, a chelator of metal ions, which 312 
induces iron starvation and leads consequently to the induction of toxin synthesis, since transcription 313 
of the tox gene is regulated by the iron-dependent transcriptional regulator DtxR. 314 
In response to bipyridyl addition, a band with an apparent molecular mass of 62 kDa was 315 
observed for toxigenic strains, which was absent without starvation and also not found in cell 316 
extracts of non-toxigenic strains. The corresponding protein for the toxigenic strain NCTC 13129 317 
was only poorly visible, indicating a low toxin production (Fig. 4). In addition to the bands 318 
corresponding to diphtheria toxin, immune reactions of DAT with different proteins in toxigenic and 319 
non-toxigenic strains were observed. One protein with an apparent molecular mass marginally 320 
higher than the toxin was detected in all strains and under iron surplus and iron starvation. 321 
Furthermore, a number of bands corresponding to polypeptides with an apparent molecular mass 322 
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between 25 and 65 kDa were observed, supporting the idea that toxoid preparations induce 323 
antibodies directed other proteins besides the inactivated diphtheria toxin.  324 
 325 
3.5. Antibody response to corynebacterial proteins of humans vaccinated with diphtheria toxoid 326 
To determine the immune reaction of humans after vaccination with diphtheria toxoid vaccines, 327 
Western Blot analyses with human sera were carried out. The adult human donors of these blood 328 
samples had undergone a hematopoietic stem cell transplantation. As part of therapy, the patients’ 329 
immune system was depleted before transplantation and had later to be rebuilt by the transplanted 330 
hematopoietic stem cells. Consequently, freshly vaccinated donors six month after stem cell 331 
transplantation were expected to show a negligible immune response, while one year after the first 332 
vaccination and carried out consecutive booster vaccinations, antibodies should be generated. The 333 
use of sera from these patients avoids the problem that healthy adult individuals vaccinated during 334 
childhood may have responded against environmental corynebacteria during their lifetime and show 335 
cross-reactions due to this contact. Any observed immunoreactivity therefore would not necessarily 336 
be directed against the proteins in the vaccine in this case.  337 
When sera from three individuals taken six months after transplantation but before booster 338 
vaccination were tested, only minor immune reactions were observed (Fig. 5a). In contrast, when 339 
sera one year after primary vaccination and consecutive booster vaccinations were applied, a strong 340 
immune reaction against a protein with apparent molecular mass of 62 kDa was observed for cell 341 
extracts of all toxigenic strains, especially when iron starvation was induced (Fig. 5b, panels 2, 4 and 342 
10). Besides this main reaction against the diphtheria toxin, additionally bands corresponding to 343 
proteins of an apparent molecular mass between 25 and 65 kDa were observed. In principle, these 344 
might be truncated forms of the toxin; however, additional bands were also found for cell extracts of 345 
four of the seven non-toxigenic isolates tested (Fig. 5b, panels 1, 3, 5 and 6). Obviously, the sera of 346 
the vaccinated adults tested contained antibodies directed against other proteins than the toxin. The 347 
number of these immune-reactive proteins correlated with the evolutionary distance of strains. Non-348 
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toxigenic C. diphtheriae strains, which are more closely related to PW8 production strains, showed 349 
more bands in Western blots compared to more distantly related isolates (Fig. S1). 350 
To further support the idea that the PW8-derived toxoid vaccines induce antibodies directed 351 
against additional proteins only in related C. diphtheriae strains, we also tested three toxigenic and 352 
two non-toxigenic C. ulcerans isolates in Western blot experiments. In fact, when grown without 353 
bipyridyl, none of the strains showed an antibody reaction with the three human sera tested. In 354 
contrast, in case of the three toxigenic isolates KL756, KL758 and KL785, a clear band attributed to 355 
the toxin was observed, in extracts from iron-starved cells. Obviously, the diphtheria toxoid vaccine 356 
is also active against C. ulcerans diphtheria toxin while immunization does not induce significant 357 
levels of antibodies directed against other C. ulcerans proteins (Fig. 6).  358 
 359 
4. Discussion 360 
The development of diphtheria toxoid vaccine is without any doubt a milestone in history of medicine 361 
and mankind. Its introduction saved the life of millions of children; however, especially the large 362 
scale outbreak starting 1990 in the Russian Federation and Ukraine [14-16] demonstrated that 363 
diphtheria is not defeated and eradicated and that surveillance and research are still necessary 364 
[2,26].  365 
In this study, we identified 665 distinct proteins in addition to the diphtheria toxin in six 366 
vaccines from different sources around the world. This astonishingly high number corresponding to 367 
about one fifths of the proteins encoded in the C. diphtheriae genome is the result of physiological 368 
protein secretion, shearing of cell surface proteins and cell lysis as indicated by the predicted 369 
localization of proteins. Since between 130 and 436 proteins were observed in the vaccine samples 370 
from the different manufacturers, cultivation and production process seem to have a major influence 371 
on the protein composition. Bioinformatics analyses of the 65 proteins common in all six vaccines 372 
studied here revealed that at least 60 proteins are predicted antigens which may induce antibody 373 
formation upon vaccination. In addition, Western blot experiments showed that antibodies of 374 
vaccinated persons are directed against different C. diphtheriae proteins besides the toxin. Putative 375 
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target proteins identified by mass spectrometry, which may influence the outcome of infection since 376 
antibodies against these proteins may result in a decreased fitness of the pathogen, are 377 
components of iron uptake systems, proteases, superoxide dismutase and catalase. The latter 378 
enzyme, found in all vaccine sample and one of the most abundant proteins in the Russian vaccine, 379 
is crucial for detoxification of reactive oxygen species secreted by host cells upon infection. Effects 380 
of vaccination on general pathogen fitness were already suggested for Clostridium botulinum since 381 
in this case administration of toxoid vaccines to cows reduced the number of C. botulinum spores in 382 
feces significantly [63].  383 
Although it was previously suggested that DT vaccines only induce immune responses 384 
against the toxin but are not effective against non-toxigenic strains that are increasing isolated from 385 
cases of systemic infections [24,32,52,64], our data indicate that also the distribution of C. 386 
diphtheriae strains may be affected by vaccination. The human antisera tested showed a strain-387 
dependent antibody binding and diphtheria toxoid vaccines may consequently not only put toxigenic 388 
strains at disadvantage, but also impair non-toxigenic strains, especially in case that these are 389 
taxonomically closely related to the PW8 production strains. The phenomenon that vaccination 390 
influence population and genetic drift of strains is discussed for Bordetella pertussis [65,66]. In this 391 
species, vaccination is assumed to affect the evolution of strains based on the observation that the 392 
molecular clock rate of mutations correlated with the vaccination coverage [67]. An effect of 393 
vaccination on B. pertussis strains was reported for the pertactin gene. The prn1 allele, which is 394 
present in the vaccine strain, was predominant in the pre-vaccine era. After introduction of the 395 
whole-cellular vaccine, strains carrying the prn2 allele increased from 39 % (1993-1996) to 90 % 396 
(1998-2004) [67, for review see 69]. Moreover, a study from Sweden showed a shift in the serotype 397 
of B. pertussis populations from serotype Fim2 in unvaccinated populations to serotype Fim3 and 398 
serotype Fim2,3 in vaccinated populations [69]. 399 
In case of C. diphtheriae, studies on allelic replacements over time are not practical due to 400 
use of the toxoid vaccine for decades; however, the results obtained here may provide a basis for 401 
studies on genomic variations and the clonal distribution of toxigenic and non-toxigenic C. 402 
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diphtheriae strains. From the amount of cross-reactions observed, the prediction can be made that 403 
strains closely related to PW8 should be at disadvantage compared to more distantly-related strains, 404 
a hypothesis, which can be tested in future taxonomical investigations. 405 
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Tables 619 
 620 
Table 1. Vaccines used for proteome analyses in this study. Sample size indicates the number of 621 
doses pooled and prepared for mass spectrometry analysis. 622 
 623 
Manufacturer/designation Active components Country Sample size 
Biological E (BE), Vacina contra 
a difteria e tétano 
 
Tetanus toxoid ≥ 20 I.U., 
diphtheria toxoid ≥ 2 I.U. 
India 3 x 10 doses (0.5 
ml per dose), two 
different lots 
Butanan Institute, Vacina 
adsorvida difteria e tétano adulto 
(dT) 
 
Tetanus toxoid ≥ 25 Lf/ml, 
diphtheria toxoid ≥ 2 Lf/ml 
Brazil 10 doses (0.5 ml 
per dose) 
GlaxoSmithKline (GSK), 
Td-pur 
Tetanus toxoid ≥ 20 I.U., 
diphtheria toxoid ≥ 2 I.U. 
Germany 10 doses (0.5 ml 
per dose) 
InterVax for BB-NCIPD, Diftet 
Vacuna DT 
 
Tetanus toxoid ≥ 20 Lf/ml, 
diphtheria toxoid ≥ 30 
Lf/ml 
Bulgaria 10 doses (0.5 ml 
per dose) 
Microgen, Diphtheria toxoid 
adsorbed (AD-M-toxoid) 
Diphtheria toxoid ≥ 10 
Lf/ml 
Russia 2 x 10 doses (0.5 
ml per dose) 
Microgen, Diphtheria-tetanus 
toxoid adsorbed 
(ADT-M-toxoid) 
Tetanus toxoid ≥ 10 
EC/ml, diphtheria toxoid ≥ 
10 Lf/ml 
Russia 2 x 10 doses (0.5 
ml per dose) 
 624 
  625 
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Table 2. Bacterial strains used in this study. 626 
 627 
C. diphtheriae 
strain 
GenBank 
accession no. 
tox gene Description/source Reference 
ATCC 27010 
(NCTC 11397) 
GCA_001457455.1 -1)  [70,71] 
ATCC 27012 CP003210 +2) Laboratory strain [72] 
DSM 43988 GCA_000455785.1 - Throat culture [73] 
DSM 43989 LJXS00000000.1 +  [70] 
INCA 402 CP003208 - Pneumonia (cancer 
patient) 
[72] 
ISS 3319 JAQO00000000 - Severe 
pharyngitis/tonsillitis 
[51,74] 
ISS 4060 JAQN00000000 - Severe 
pharyngitis/tonsillitis 
[51] 
ISS 4749 JAQQ00000000 - Severe 
pharyngitis/tonsillitis 
[51] 
HC04 CP003215 - Fatal case of 
endocarditis 
[72] 
NCTC 13129 BX248353 + Diphtheria [75] 
C. ulcerans 
strain 
GenBank 
accession no. 
tox gene Description/source Reference 
809 CP002790.1 - Human [76] 
BR-AD22 CP002791.1 - Dog [77] 
KL 756 - + Dog This study 
KL 758 - + Human This study 
 26 
KL 785 - + Human This study 
 628 
1) –: absent, 2) +: present 629 
 630 
  
Table 3. Proteins identified in all analyzed vaccine samples. Annotation and predicted localization as well as localization signals are given 631 
for the identified proteins. The number of strains in which the proteins are conserved among 117 C. diphtheriae sequences analyzed are 632 
indicated as “prevalence” and a previous identification of these proteins in different proteome analyses is shown. 633 
 634 
Identifier Localization  
[51]  
Prevalence Antigen 
 
Annotation [39] [62] [61] 
DIP0025 Cyt 117 + Peptidyl-prolyl cis-trans isomerase Yes No Yes 
DIP0108 Sec-Lipo 116 + Ferrisiderophore receptor Irp6A Yes No Yes 
DIP0154 Cyt 117 - Putative endopeptidase No No No 
DIP0169 Tat-Lipo 117 - Putative secreted protein No No No 
DIP0178 Cyt 117 + Putative phenylalanine aminotransferase No No No 
DIP0222 Sec-SpI 49 + Diphtheria toxin No No No 
DIP0225 Sec-Lipo 111 + Putative secreted polysaccharide deacetylase Yes No No 
DIP0257 Cyt 108 + Uncharacterized protein No No No 
DIP0281 Sec-NC 117 + Catalase Yes No Yes 
DIP0350 Sec-SpI 101 + Putative secreted protease Yes No No 
DIP0365 Sec-SpI 117 + Surface layer protein A Yes No No 
DIP0368 Cyt 117 + Dihydrolipoyl dehydrogenase No No No 
DIP0383 Cyt 117 + Uncharacterized protein Yes No No 
 28 
DIP0442 TM-Sec 117 + Putative membrane protein No No No 
DIP0469 Cyt 117 + Elongation factor G Yes No Yes 
DIP0470 Cyt 117 + Elongation factor Tu No No Yes 
DIP0483 Amb 116 + Putative secreted protein No No No 
DIP0491 Sec-SpI 116 + Putative secreted amino acid hydrolase No No No 
DIP0515 Tat-Lipo 117 + Putative transport system secreted protein No No No 
DIP0534 Sec-Lipo 117 + Putative sugar-binding secreted protein Yes No No 
DIP0543 TM-Sec 114 + Putative sialidase Yes No No 
DIP0575 Cyt 117 + 10 kDa chaperonine Yes No No 
DIP0582 Sec-Lipo 117 + 
Putative iron transport system binding (secreted) 
protein 
Yes No No 
DIP0611 Sec-Lipo 117 + Putative ABC transport system secreted protein No No No 
DIP0615 Sec-Lipo 117 + ABC transport system exported protein No No No 
DIP0631 Cyt 117 + Isocitrate dehydrogenase [NADP] No No No 
DIP0680 Amb 117 + Uncharacterized protein Yes No No 
DIP0775 Sec-SpI 114 + Uncharacterized protein Yes No No 
DIP0856 TM 117 + Putative serine protease No No No 
DIP0917 Cyt 117 + Enolase Yes No No 
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DIP0956 Sec-Lipo 117 + 
Putative peptide transport system secreted 
protein 
Yes No No 
DIP1062 Sec-Lipo 117 + 
Putative iron siderophore uptake system exported 
solute-binding component 
Yes No No 
DIP1086 Sec-Lipo 117 + 
Putative iron transport system exported solute-
binding component 
No No No 
DIP1100 Cyt 117 + Ketol-acid reductoisomerase (NADP(+)) No No No 
DIP1204 Cyt 117 + Oxoglutarate dehydrogenase inhibitor No No No 
DIP1229 Cyt 116 + Putative cobalamin biosynthesis related protein No No No 
DIP1303 Cyt 117 + Transaldolase No No Yes 
DIP1308 Cyt 117 + Triosephosphate isomerase No No No 
DIP1309 Cyt 117 - Phosphoglycerate kinase Yes No Yes 
DIP1310 Cyt 117 + Glyceraldehyde-3-phosphate dehydrogenase Yes No No 
DIP1390 Sec-Lipo 115 + Putative secreted protein No No No 
DIP1419 Cyt 117 + Alkyl hydroperoxide reductase AhpD Yes No No 
DIP1420 Cyt 117 + Iron repressible polypeptide (putative reductase) Yes No No 
DIP1482 Cyt 117 + Proline-tRNA ligase No No No 
DIP1505 Cyt 117 + Ribosome-recycling factor Yes No No 
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DIP1586 Sec-Lipo 117 + Putative secreted protein No No No 
DIP1636 Cyt 117 + Branched-chain-amino-acid aminotransferase No No No 
DIP1637 Cyt 117 + Probable cytosol aminopeptidase No No No 
DIP1644 Cyt 117 + Glutamine synthetase No No No 
DIP1667 TM 116 + Putative membrane protein No No No 
DIP1680 Cyt 117 + GTP cyclohydrolase 1 type 2 homolog No Yes No 
DIP1783 Cyt 117 + Nucleoside diphosphate kinase No No Yes 
DIP1786 Cyt 117 + Valine-tRNA ligase No No No 
DIP1787 Cyt 117 + Malate dehydrogenase No No Yes 
DIP1902 Cyt 116 + Succinyl-CoA:coenzyme A transferase No No Yes 
DIP2010 TM-Sec-LPXTG 88 + Putative surface-anchored membrane protein No No No 
DIP2120 Cyt 117 + Chaperone protein DnaK Yes No No 
DIP2128 Sec-Lipo 116 + Putative substrate-binding transport protein No No No 
DIP2169 TM 111 + Putative membrane protein No No No 
DIP2180 Cyt 116 - Phosphoenolpyruvate carboxykinase No No No 
DIP2193 Sec- SpI 117 + Putative secreted protein Yes No No 
DIP2261 Cyt 117 + Superoxide dismutase [Mn] No No No 
DIP2290 Sec-NC 117 + Single-stranded DNA-binding protein No No No 
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DIP2331 Cyt 117 - Putative aldehyde dehydrogenase No No No 
635 
  
Figure legends 636 
 637 
Figure 1. Influence of heat-treatment on patterns of vaccine proteins form Td-pur (GSK). Proteins 638 
were separated by a 12.5 % (w/v) Tricine-buffered SDS-PAGE. The proteins were precipitated by 639 
TCA extraction and resuspended in 50 µl rehydration buffer. Approximately 125 µg of protein was 640 
loaded per lane. The separated proteins were silver-stained. Lane 1: protein marker, lane 2: without 641 
boiling, lane 3: 95 °C for 5 min with loading dye, lane 4: 95 °C for 20 min in addition to 95 °C for 5 642 
min with loading dye.  643 
 644 
Figure 2. Bioinformatics analysis of proteins identified in diphtheria toxoid vaccines. (a) Venn 645 
diagram [78] of identified proteins in the different samples. Country of origin is given (Russia 1: 646 
Diphtheria Toxoid, Russia 2: Diphtheria-Tetanus Toxoid). (b) Predicted localization of 65 proteins 647 
present in all vaccines studied. Proteins located in the cytoplasm are shown in medium grey, 648 
secreted proteins in dark grey, membrane proteins in light grey and proteins with ambiguous 649 
localization in black. 650 
 651 
Figure 3. Quantitative protein analysis. 250 ng of prepared vaccine samples were analyzed by mass 652 
spectrometry. The relative protein amount of diphtheria toxin (DT), the two most prominent proteins 653 
beside DT and of the remaining proteins was calculated. Only proteins in a range from 2 x 107 to 654 
1011 where considered for calculation. 655 
 656 
Figure 4. Western blots of cell extracts from toxigenic and non-toxigenic C. diphtheriae strains. 657 
Bacteria were grown without (-) and with (+) bipyridyl, which induces iron starvation. 2 µg of protein 658 
extract were added per lane. Diphtheria antitoxin produced in horses for therapy was used as 659 
primary antibody. 1: ATCC 27010 (tox-), 2: ATCC 27012 (tox+), 3: DSM 43988 (tox-), 4: DSM 43989 660 
(tox+), 5: INCA 402 (tox-), 6: ISS 3319 (tox-), 7: ISS 4060 (tox-),  661 
 33 
8: ISS 4749 (tox-), 9: HC04 (tox-), 10: NCTC 13129 (tox+). The arrow indicates the diphtheria toxin 662 
with an apparent molecular mass of 62 kDa, the asterisk a protein with slightly higher apparent 663 
molecular mass present in all cell lysates. 664 
 665 
Figure 5. Western blots of C. diphtheriae cell extracts. Toxigenic and non-toxigenic strains were 666 
grown without (-) and with (+) bipyridyl. 2 µg of protein extract were added per lane. Serum from 667 
three different donors (K002, K003 and K009), six months after hematopoietic stem cell 668 
transplantation (first serum) (Fig. 5a) and 1 year after primary and two booster vaccinations (second 669 
serum) (Fig. 5b) was used as primary antibody. 1: ATCC 27010 (tox-), 2: ATCC 27012 (tox+), 3: 670 
DSM 43988 (tox-), 4: DSM 43989 (tox+), 5: INCA 402 (tox-), 6: ISS 3319 (tox-), 7: ISS 4060 (tox-), 8: 671 
ISS 4749 (tox-), 9: HC04 (tox-), 10: NCTC 13129 (tox+). Diphtheria toxin is indicated by an arrow. 672 
 673 
Figure 6. Western blots of C. ulcerans cell extracts. Proteins from strains grown without (-) and with 674 
bipyridyl (+) were separated by SDS-PAGE. Human serum from three individual donors (a: K002, b: 675 
K003 and c: K009), collected 1 year after primary and two booster vaccinations (second serum) was 676 
used as primary antibody. 1: 809 (tox-), 2: BR-AD22 (tox-), 3: KL 756 (tox+), 4: KL 758 (tox+) and 5: 677 
KL 785 (tox+). Diphtheria toxin is indicated by an arrow. 678 
 679 
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